Cargando...
Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
Upadacitinib is a selective Janus Kinase 1 inhibitor which is being developed for the treatment of several inflammatory diseases including rheumatoid arthritis. Upadacitinib was evaluated in Phase 3 studies as an oral extended-release (ER) formulation administered once daily. The purpose of this stu...
Gardado en:
| Publicado en: | AAPS J |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer International Publishing
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6814631/ https://ncbi.nlm.nih.gov/pubmed/31654328 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-019-0378-y |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|